[Drug-drug interactions in critically ill patients]

Area of Science:

• Pharmacology
• Critical Care Medicine

Context:

• Critically ill patients are highly susceptible to adverse drug-drug interactions (DDIs).
• Drug interactions can manifest as pharmacodynamic (causing organ damage) or pharmacokinetic (altering drug metabolism and transport).

Purpose:

• To highlight the risks of drug-drug interactions in critically ill patients.
• To discuss the mechanisms of pharmacokinetic interactions involving cytochrome P450 enzymes and P-glycoprotein.
• To identify common drugs involved in DDIs and propose strategies for prevention.

Summary:

• Pharmacokinetic DDIs, driven by enzyme inhibition or induction (e.g., cytochrome P450, P-glycoprotein), can lead to toxic or subtherapeutic drug levels.
• Commonly implicated drugs include amiodarone, macrolides, azoles, anticoagulants, immunosuppressants, rifampicin, and CNS-active agents.
• Preventive strategies involve risk-benefit assessment, therapeutic drug monitoring, electronic alert systems, and clinical evaluation.

Impact:

• Understanding DDIs is vital for preventing organ damage and ensuring effective pharmacotherapy in critical care settings.
• Implementation of monitoring and alert systems can significantly reduce the incidence of adverse drug events.
• This knowledge supports safer medication management for vulnerable patient populations.